Auxilius, a company specializing in Clinical Trial Financial Management (CTFM) software for the biopharma industry, has recently raised $10 million in financing led by SignalFire. With an astounding 800% year-over-year growth in annual recurring revenue (ARR) for 2023, this upsurge underscores the
Spur Therapeutics, previously known as Freeline Therapeutics, is making waves in the field of genetic medicine with its rebranding and renewed mission to revolutionize the treatment of chronic diseases through gene therapy. The company's ambitious initiatives encompass innovative research,
Freeline Therapeutics, known for its pioneering work in gene therapy, has unveiled a new identity and an expanded mission, rebranding itself as Spur Therapeutics. This transformation marks a significant step towards a broader and more ambitious vision that includes tackling both rare genetic
Advancements in cancer treatments have always been a focal point in medical research. Mustang Bio, Inc. (Nasdaq: MBIO) has recently made significant strides in the battle against Waldenstrom macroglobulinemia (WM), a rare type of blood cancer. Their latest clinical trial results for MB-106, a
The biopharma industry stands at the crossroads of innovation and necessity as it leans into the burgeoning field of immunology. With the global immunology market anticipated to grow exponentially in the coming years, reaching numbers second only to oncology, major players and emerging startups
Throughout 2023 and 2024, the U.S. Food and Drug Administration (FDA) played a pivotal role in the pharmaceutical and biotechnology sectors, not only by approving a significant number of new drugs but also by pushing the boundaries of innovation. These two years were marked by a notable surge in
